Highest-materiality recent filing
MySize Q1 revenue up 62% to $2.39M; gross margin expands to 39.3%, net loss widens to $1.48M
Revenue increased 62% YoY to $2.39 million; gross profit up 124% to $940,000.
MySize receives Nasdaq bid price deficiency notice; reports preliminary 2025 revenue ~$10M
Nasdaq notified MySize on March 2, 2026 that its common stock bid price closed below $1.00 for 30 consecutive days; 180-day cure period until August 31, 2026.
My Size receives Nasdaq delisting notice for bid price below $1.00; has until Aug 31, 2026 to cure
Nasdaq notified My Size on March 2, 2026 that bid price was below $1.00 for 30 consecutive trading days.
MySize expects FY2025 revenue ~$10M, ~$4M cash; targets ~$15M in 2026
Preliminary FY2025 revenue of approximately $10 million; estimated cash balance of $4 million at year-end.
My Size awards 400,000 restricted shares to execs; CEO Luzon receives 200,000
Compensation Committee approved restricted stock awards (RSAs) on Dec 15, 2025, under the 2017 Equity Incentive Plan.
MySize Q3 2025 revenue $2.6M, up 26% sequentially; net loss narrows to $2.8M
Revenue of $2.6 million, up 26% sequentially from Q2 2025.
My Size acquires ShoeSize.Me for $440K (cash+stock) plus warrant; adds AI footwear sizing
Acquired ShoeSize.Me AG for $150K cash, 241,093 shares (~$290K), and a 28K-share milestone warrant.
My Size shareholders approve equity plan amendment and elect directors at 2025 annual meeting
Shareholders elected Arik Kaufman and Roy Golan as Class I directors for three-year terms.
MySize Q2 revenue $2.0M (+2% YoY); operating loss narrows 49%; Percentil adds $180k
Q2 revenue $2.0M (+2% YoY); H1 revenue $3.5M (-30% YoY) on Orgad market decline.
My Size reprices employee options to $1.28; accelerates vesting for 18,750 shares for former CFO
Compensation Committee reduced exercise price of 13,926 shares from $3.832–$8.72 to $1.28, the June 4 closing price.
MySize acquires Percentil assets for ~$679k; expects $1.5M revenue in H2 2025
Acquired production unit of Casi Nuevo Kids (Percentil) for €610,807 (~$679k) in cash and assumed liabilities.
My Size FY 2024 revenue up 18% to $8.26M, cash more than doubles to $4.88M
Revenue $8.26M (+18% YoY); net loss narrowed 37% to $3.99M.
My Size announces CFO resignation, appoints Oren Elmaliah as new CFO and Roy Golan to board
CFO Or Kles resigned effective March 31, 2025 (previously disclosed).
My Size enters ATM equity offering with H.C. Wainwright for up to $4.1M
Entered into an at-the-market offering agreement with H.C. Wainwright to sell up to $4.1 million of common stock.
My Size CFO Or Kles resigns effective March 31, 2025; search underway
Or Kles notified My Size on January 14, 2025 of his resignation as CFO.
My Size shareholders elect Ronen Luzon as Class III director, ratify accountant at annual meeting
Stockholders elected Ronen Luzon as Class III director with 298,026 votes for, 4,830 against, 2,600 abstentions, excluding 321,356 broker non-votes.
My Size raises ~$3.0M from warrant exercise of 653,028 shares
653,028 warrants from the May 2024 repricing were exercised on Dec 27, 2024.
MySize preliminary 2024 revenue $8.5M (+23% YoY), targets $15M for 2025
Preliminary 2024 revenue of $8.5M, up 23% YoY; project $15M revenue in 2025 based on current conditions.
MySize Q2 revenue up 53% to $1.97M, net loss narrows 25% to $964K
Revenue of $1.97M (+53% YoY) driven by Orgad growth and Naiz Fit SaaS revenue.
My Size raises ~$3.26M via warrant exercise inducement; issues new warrants for up to 1.34M shares
Holder exercises 670,989 existing warrants at reduced price of $4.86/share; gross proceeds ~$3.26M.
MySize Q1 revenue jumps 314% to $2.98M; net loss narrows 61% to $1.02M
Revenue $2.98M (+314% YoY); SaaS revenue $177K (+25%).
My Size regains Nasdaq compliance; bid price above $1.00 for 10 days
Nasdaq confirmed My Size regained compliance with Listing Rule 5550(a)(2) on May 7, 2024.
My Size approves 1-for-8 reverse stock split to maintain Nasdaq listing
Stockholders approved reverse split authority at April 15 special meeting; vote was 1.73M for, 0.72M against.
As previously disclosed, Or Kles, the Chief Financial Officer of My Size, Inc. (the “Company”) resigned effective March 31, 2025.
On March 6, 2025, the Company appointed Oren Elmaliah as the Company’s Chief Financial Officer, effective April 1, 2025 to replace Mr. Kles.
Mr. Golan was additionally appointed to the Audit Committee as chair, the Compensation Committee, and Nominating and Corporate Governance Committee.
on March 6, 2025, the Company’s board of directors appointed Roy Golan as a Class I director to replace Mr. Elmaliah, effective immediately.
As a then member of the board of directors of the Company, Mr. Elmaliah stepped down as a member of the board and all committees of the board of directors of the Company.
On January 14, 2025, Or Kles, Chief Financial Officer of My Size, Inc. (the “Company”), notified the Company of his decision to resign as the Company’s CFO, to be effective March 31, 2025.
Max materiality 0.75 · Median 0.65 · Most common event earnings